NeoGenomics buys VC-backed Inivata for $390m

  • by


Nasdaq-listed cancer diagnostics specialist NeoGenomics has acquired a majority stake in Cambridge-based Inivata – a cancer genomics company backed by a pool of VC investors – for $390m.



Source link

Leave a Reply

Your email address will not be published.